Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 10:11:1708.
doi: 10.3389/fimmu.2020.01708. eCollection 2020.

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Yujun Tang  1 , Jiajia Liu  1 , Dingyi Zhang  1 , Zhenghao Xu  1 , Jinjun Ji  1 , Chengping Wen  1
Affiliations
Review

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Yujun Tang et al. Front Immunol. .

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has caused 347,192 deaths around the world. The current evidence showed that severely ill patients tend to have a high concentration of pro-inflammatory cytokines, such as interleukin (IL)-6, compared to those who are moderately ill. The high level of cytokines also indicates a poor prognosis in COVID-19. Besides, excessive infiltration of pro-inflammatory cells, mainly involving macrophages and T-helper 17 cells, has been found in lung tissues of patients with COVID-19 by postmortem examination. Recently, increasing studies indicate that the "cytokine storm" may contribute to the mortality of COVID-19. Here, we summarize the clinical and pathologic features of the cytokine storm in COVID-19. Our review shows that SARS-Cov-2 selectively induces a high level of IL-6 and results in the exhaustion of lymphocytes. The current evidence indicates that tocilizumab, an IL-6 inhibitor, is relatively effective and safe. Besides, corticosteroids, programmed cell death protein (PD)-1/PD-L1 checkpoint inhibition, cytokine-adsorption devices, intravenous immunoglobulin, and antimalarial agents could be potentially useful and reliable approaches to counteract cytokine storm in COVID-19 patients.

Keywords: COVID-19; antimalarial agents; cytokine storm; immunoregulation; tocilizumab; treatment strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Artemisinin-family drugs for cytokine storm in COVID-19. The dysregulation of the cytokine storm involves mainly APCs. TLR2 and TLR4 locate mainly outside macrophages, DCs, and granulocytes. Also, they are expressed within endosomes, play a role in recognizing bacteria and viruses. Through MyD88-dependent or TRIF-dependent pathway, TLR2 and TLR4 transmit signals for the activation of IRF3 and NF-κB to induce the type I interferon and cytokines. Besides, TLR2 leads to the activation of AP-1, which is responsible for the transcription of inflammatory cytokines. The cytokines target at the naïve T helper cell, to result in the naïve T helper cell to differentiate to Th1 cell and Th17 cell, subsequently to secrete the inflammatory cytokines and chemokines. Moreover, the IL-6, IL-8, and IL-10 secreted by monocytes and macrophages could activate cytokines receptors (i.e., IL-6R, IL-8R), lead to the activation of JAK-STAT signaling pathways and cell migration. The artemisinin-family drugs target at a variety of molecules (red and blueness nodes) in the inflammatory networks, such as NF-κB, IRF3, ERK (not shown in the figure), and RORγt, which inhibit the differentiation of inflammatory cells and the production of cytokines and chemokines. IL-10 is an anti-inflammatory cytokine. It could be secreted by virtually all immune cells, including macrophages, DCs, NK cells, T cells, and B cells. At the moment, the high concentration of IL-10 in severely ill patients with COVID-19 is a mystery. On the one hand, it might play a role in antagonizing the biological function induced by IL-6. On the other hand, the high concentration of IL-10 might contribute to the lymphocytes exhaustion. AP-1, activating protein-1; CCL, C-C motif chemokine ligand; CXCL, C-X-C motif chemokine ligand; IKK, IκB kinase; IFN, interferon; IRF3, interferon response factor 3; JAK, Janus kinase; JNK, Jun N-terminal kinase; MyD88, myeloid differentiation primary response protein 88; NF-κB, Nuclear factor κ B; NLPR3, NOD-, LRR- and pyrin domain-containing protein 3; MKK, Mitogen-activated protein kinase kinase; SMAD5, SMAD Family Member 5; RORγt, retinoic acid receptor-related orphan nuclear receptor gamma t; STAT, Signal transducer and activator of transcription; TAK1, TGFβ-activated kinase; T-bet, T-box transcription factor 21 (also known as TBX21); TLR, Toll-like receptor; TRAF, TNF receptor-associated factor; TRAM, TRIF-related adaptor molecule; TRIF, TIR domain–containing adaptor protein inducing interferon-β. IL, interleukin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cron R, Behrens EM. Cytokine Storm Syndrome. 1 ed Cham: Springer Nature Switzerland AG; Springer International Publishing; (2019).
    1. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. (2012) 76:16–32. 10.1128/MMBR.05015-11 - DOI - PMC - PubMed
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9. 10.1001/jama.2020.1585 - DOI - PMC - PubMed
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. 10.1056/NEJMoa2002032 - DOI - PMC - PubMed
    1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. (2020) 130:2620–9. 10.1101/2020.02.16.20023903 - DOI - PMC - PubMed

Publication types

MeSH terms